Skip to Main Content U.S. Department of Energy
Economic Development Office

Tri-Cities Tech Business Update

February 2010 Issue

New R&D vice-president at IsoRay


William Cavanagh has joined Richland, Wash.-based IsoRay, Inc. as the company's vice-president of research and development. He has been involved in cancer treatment research and development for more than 20 years and most recently served as the chief scientific officer for Seattle, Wash.-based Sangretech Biomedical. IsoRay is the sole producer of the Cesium-131 brachytherapy seed, which is currently used in the treatment of prostate cancer and ocular melanoma among other cancerous conditions.

Contact at 520-240-4840.

PNNL's EDO

News & Events

Programs & Resources

Share This

Share This!

Additional Information

Subscribe

Current Issue

Back Issues